Phosphoramidate ProTides of 2'-C-Methylguanosine as highly potent inhibitors of hepatitis C virus. Study of their in vitro and in vivo properties

McGuigan, Christopher ORCID: https://orcid.org/0000-0001-8409-710X, Gilles, Arnaud, Madela, Karolina, Aljarah, Mohamed, Holl, Sabrina, Jones, Sarah Louise, Vernachio, John, Hutchins, Jeff, Ames, Brenda, Bryant, K. Dawn, Gorovits, Elena, Ganguly, Babita, Hunley, Damound, Hall, Andrea, Kolykhalov, Alexander, Liu, Yule, Muhammad, Jerry, Raja, Nicholas, Walters, Robin, Wang, Jin, Chamberlain, Stanley and Henson, Geoffrey 2010. Phosphoramidate ProTides of 2'-C-Methylguanosine as highly potent inhibitors of hepatitis C virus. Study of their in vitro and in vivo properties. Journal of Medicinal Chemistry 53 (13) , pp. 4949-4957. 10.1021/jm1003792

Full text not available from this repository.

Abstract

Hepatitis C virus infection constitutes a serious health problem in need of more effective therapies. Nucleoside analogues with improved exposure, efficacy, and selectivity are recognized as likely key components of future HCV therapy. 2′-C-Methylguanosine triphosphate has been known as a potent inhibitor of HCV RNA polymerase for some time, but the parent nucleoside is only moderately active due to poor intracellular phosphorylation. We herein report the application of phosphoramidate ProTide technology to bypass the rate-limiting initial phosphorylation of this nucleoside. Over 30 novel ProTides are reported, with variations in the aryl, ester, and amino acid regions. l-Alanine compounds are recognized as potent and selective inhibitors of HCV in replicon assay but lack rodent plasma stability despite considerable ester variation. Amino acid variation retaining the lead benzyl ester moiety gives an increase in rodent stability but at the cost of potency. Finally l-valine esters with ester variation lead to potent, stable compounds. Pharmacokinetic studies on these agents in the mouse reveal liver exposure to the bioactive triphosphate species following single oral dosing. Systemic exposure of the ProTide and parent nucleoside are low, indicating possible low toxicity in vivo, while liver concentrations of the active species may be predictive of efficacy in the clinic. This represents one of the most thorough cross-species studies of ProTides to date.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Pharmacy Systems Immunity Research Institute (SIURI)
Subjects:	R Medicine > RS Pharmacy and materia medica
Publisher:	American Chemical Society
ISSN:	0022-2623
Last Modified:	17 Oct 2022 10:08
URI:	https://orca.cardiff.ac.uk/id/eprint/6963

Citation Data

Cited 49 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item